CIA
BIO icon

Concurrent Investment Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Concurrent Investment Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$578K Sell
1,970
-192
-9% -$54.5K ﹤0.01% 1317
2026
Q1 		$603K Sell
2,162
-954
-31% -$275K 0.01% 1120
2025
Q4 		$944K Buy
+3,116
New +$972K 0.01% 863

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Concurrent Investment Advisors's BIO Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Bio-Rad Laboratories Class A (BIO) stake by 8.9% in Q2 2026, selling an estimated $54.5K and leaving 1,970 shares worth $578K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

Concurrent Investment Advisors first reported a position in BIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $944K in Q4 2025. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Concurrent Investment Advisors held 1,970 shares of Bio-Rad Laboratories Class A worth $578K as of Q2 2026.
  • Concurrent Investment Advisors sold 192 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $54.5K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1317 holding.
  • Concurrent Investment Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and has held it in 3 quarters since.
  • Concurrent Investment Advisors's Bio-Rad Laboratories Class A position peaked at $944K in Q4 2025.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.